Is GH a Buy? What to Consider in 2026

The case for Guardant Health right now is Shield colorectal screening ramp, with revenue (q1 2026 quarterly) at ~$302 million, up 48% year over year. If you believe that thesis holds, GH is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples.

Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is rapid revenue growth, an FDA-approved Shield screening test entering a large market, and a targeted 2027 cash-flow breakeven. The bear case is ongoing losses and cash burn, reimbursement uncertainty, strong competition, and a high price-to-sales valuation. Weigh both against your own portfolio and overlap.

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue. It sells oncology tests like Guardant360 (to match patients to targeted therapies) and Reveal (to detect residual cancer after treatment), provides testing and data services to drugmakers, and markets Shield, an FDA-approved blood test for colorectal cancer screening. It is built around the idea that a simple blood draw can guide cancer care.

Shield is a blood test for colorectal cancer screening and the first to win full FDA approval as a primary screening option for average-risk adults 45 and older. It matters because it could reach the roughly one-third of eligible people who skip colonoscopy or stool tests. Screening revenue grew to ~$41.6 million in Q1 2026 from ~$5.7 million a year earlier, and it is the company's biggest growth driver and its largest source of cash burn.

Not yet. Guardant reported an adjusted EBITDA loss of ~$59 million in Q1 2026 and continues to burn cash, largely to fund the Shield screening launch. It held roughly $1.2 billion in cash at quarter end and targets company-wide cash-flow breakeven by the end of 2027, with the core business excluding screening expected to turn cash-positive sooner. Until then, results are judged on growth and the path to breakeven rather than earnings.